Ruby Khoury, MD

Precision Alemtuzumab Dosing Results in Day 0 Target Range Achievement in 80% of IEI Patients and Minimizes Risks of GVHD, Clinically Significant Mixed Chimerism, and Secondary Graft Failure. Marsh, R; Khoury, R; Mizuno, K; Hosawi, A; Cottrell, C; Nguyen, E; Landon, B; Chandra, S; Jordan, M; Kumar, A; Bleesing, J; Davies, S; Moore, C; Mehta, P. 2025; 1.

Addition of Thiotepa to Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Reduces Secondary Graft Failure in Allogeneic HSCT for Inborn Errors of Immunity. Khoury, R; Jordan, M; Bleesing, J; Kumar, A; Saldana, BD; Verkamp, B; Davies, S; Marsh, R; Chandra, S. 2025; 1.

Effect of Clinically Relevant Immunosuppressants on Viral Specific T-Cell (VST) in Vitro Function. Lichtenstein, DA; Sridharan, A; Khoury, R; Grimley, MS; Rubinstein, JD; Lutzko, CM; Wang, YM. Transplantation and Cellular Therapy. 2025; 31:s509-s510.

Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant. Khoury, R; Grimley, MS; Nelson, AS; Leemhuis, T; Cancelas, JA; Cook, E; Wang, YZ; Heyenbruch, D; Bollard, CM; Keller, MD; Hanley, PJ; Lutzko, C; Pham, G; Davies, SM; Rubinstein, JD. American Journal of Transplantation. 2024; 24:1634-1643.

COVID-19 Vaccination in Patients with Inborn Errors of Immunity Reduces Hospitalization and Critical Care Needs Related to COVID-19: a USIDNET Report. McDonnell, J; Cousins, K; Younger, ME M; Lane, A; Abolhassani, H; Abraham, RS; Al-Tamemi, S; Aldave-Becerra, JC; Al-Faris, EH; Alfaro-Murillo, A; Lim, XR; Lopes, JP; López, AL; Tarquini, L. Journal of Clinical Immunology. 2024; 44:86.

Viral specific T cell therapy in kidney transplant recipients - A single-center experience. Anand, M; Nysather, J; McGraw, G; Apewokin, S; Khoury, R; Grimley, MS; Bumb, S; Govil, A. Transplant Infectious Disease. 2023; 25:e14179.

Viral-specific T cells for Cytomegalovirus retinitis following hematopoietic stem cell transplantation: A success story. Montiel-Esparza, R; Michalak, SM; Le, AH D; Or, C; Nguyen, QD; Khoury, R; Grimley, MS; Bertaina, A; Klinger, E; Shah, AJ; Wood, EH. Pediatric Blood and Cancer. 2023; 70:e30429.

Post CAR T-cell therapy outcomes and management in HSCT-naive patients: a single-center experience. Phillips, CL; Krupski, C; Khoury, R; Dandoy, CE; Nelson, AS; Galletta, TJ; Faulhaber, A; Davies, SM; Rubinstein, JD. Frontiers in Hematology. 2023; 2:1151744.

Durable remissions achieved with reinfusion of CD19-directed CAR-T despite failure to induce or maintain B-cell aplasia and single-center experience with reinfusion of tisagenlecleucel. Galletta, TJ; Rubinstein, JD; Krupski, C; Nelson, AS; Khoury, R; Dandoy, CE; Davies, SM; Phillips, CL. Pediatric Blood and Cancer. 2023; 70:e30271.

Third-Party and Patient-Specific Donor-Derived Virus-Specific T Cells Demonstrate Similar Efficacy and Safety for Management of Viral Infections after Hematopoietic Stem Cell Transplantation in Children and Young Adults. Galletta, TJ; Lane, A; Lutzko, C; Leemhuis, T; Cancelas, JA; Khoury, R; Wang, YZ M; Hanley, PJ; Keller, MD; Bollard, CM; Davies, SM; Grimley, MS; Rubinstein, JD. Transplantation and Cellular Therapy. 2023; 29:305-310.